

## BRIUMVI INFUSION ORDERS

FAX: 470.922.3656 | PHONE: 470.377.6400

PATIENT INFORMATION:	Fax completed form, ins	surance information, a	and clinical documentation to 470.922.3656	
Patient Name:		DOB:	Phone:	
Patient Status:	ontinuing Therapy	Next Treatmen	t Date:	
MEDICAL INFORMATION				
<b>Diagnosis:</b> Multiple Sclerosis <b>Type (required):</b> Relapsing-Remittin	g 🗌 Secondar	y-Progressive	Clinically Isolated	
ICD-10 Code: G35				
Patient Weight: lbs. (required) A	llergies:			
THERAPY ORDER				
Briumvi:				
□ Loading Dose: 150mg IV, followed by 450mg IV 2 weeks later, then 450mg IV every 24 weeks x 1 year				
☐ 450mg IV every 24 weeks x 1	year			
<b>Protocol Pre-medication Orders:</b> Solu-Medrol 100mg IV and Diphenhydramine 25mg PO or IV 30 minutes before infusion (if no contraindications)				
Additional Pre-medication Orders: _				
Lab Orders:		_ Lab Freque	ncy:	
Required labs to be drawn by:	Biocare Infus	sion 🗌 Refe	erring Provider	
Other orders:				
Anaphylactic Reaction Orders:				
<ul> <li>Epinephrine (based on patient weight)</li> <li>&gt;20kg (&gt;66kpc)) EpiDep 0.2mg or compounded surings IM or subOt more report in 5.10 minutes v1.</li> </ul>				
<ul> <li>&gt;30kg (&gt;66lbs): EpiPen 0.3mg or compounded syringe IM or subQ; may repeat in 5-10 minutes x1</li> <li>15-30kg (33-66lbs): EpiPen Jr. 0.15mg or compounded syringe IM or subQ; may repeat in 5-10 minutes x1</li> </ul>				
Diphenhydramine: Administer 25-50mg orally OR IV (adult)				
Famotidine 20mg IV as needed (adult)				
NS 0.9% 500mL IV bolus as needed (adult)				
<ul> <li>Refer to physician order or institutional protocol for pediatric dosing</li> <li>Flush orders: NS 1-20mL pre/post infusion PRN and Heparin 10U/mL or 100U/mL per protocol as indicated PRN</li> </ul>				
PROVIDER INFORMATION				
By signing this form and utilizing our services, you are authorizing <i>Bioca</i>	re Infusion, and its employees to	serve as your prior authoriz	ation and specialty pharmacy designated	
agent in dealing with medical and prescription insurance companies, and <b>Provider Name:</b>			Date:	
Provider Name:Phone:	Fax:	Co	ontact Person:	
	of care (if checked	, please list site c	of care):	
PREFERRED LOCATION				
City: State:		View our locatio	回流回 ns here: 没当	
IMPORTANT NOTICE: This fax is intended to be delivered only to applicable law. If you are not the named addressee, you should not		ns material that is confider		

this document in error.



## COMPREHENSIVE SUPPORT FOR BRIUMVI THERAPY

PATIENT INFORMATION:				
Patient Name:	DOB:			
<b>REQUIRED DOCUMENTATION FOR REFERRAL</b>	PROCESSING & INSURANCE APPROVAL			
Include signed and completed order (MD/presci	riber to complete page 1)			
Include patient demographic information and insurance information				
Include patient's medication list				
Supporting clinical notes to include any past benefits, or contraindications to therapy	tried and/or failed therapies, intolerance,			
Expanded Disability Status Scale (EDSS) so	ore:			
Include labs and/or test results to support diagn	osis			
If applicable - Last known biological therapy: If patient is switching to biolog out period of weeks prior to starting	gic therapies, please perform a wash-			
Other medical necessity:				
REQUIRED PRE-SCREENING				
Hepatitis B screening test completed. This is B core antibody total (not IgM) - attach result	••••			

□ Positive □ Negative

┘ Serum Immunoglobulins (recommended)

\*If Hepatitis B results are positive - please provide documentation of treatment or medical clearance

Biocare Infusion will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

## Please fax all information to (470) 922-3656 or call (470) 377-6400 for assistance

BIOCAREINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.